Esperion Therapeutics (NASDAQ:ESPR) Downgraded by StockNews.com

StockNews.com lowered shares of Esperion Therapeutics (NASDAQ:ESPR) from a buy rating to a hold rating in a report released on Monday morning.

ESPR has been the topic of several other reports. HC Wainwright reaffirmed a buy rating and set a $16.00 price target on shares of Esperion Therapeutics in a research note on Monday, August 12th. Bank of America cut Esperion Therapeutics from a neutral rating to an underperform rating and decreased their price objective for the stock from $2.90 to $2.50 in a report on Thursday, June 20th. Finally, Needham & Company LLC dropped their target price on Esperion Therapeutics from $8.00 to $6.00 and set a buy rating for the company in a research note on Tuesday, August 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Esperion Therapeutics has a consensus rating of Hold and a consensus target price of $8.17.

Esperion Therapeutics Trading Down 0.5 %

Shares of ESPR opened at $1.82 on Monday. Esperion Therapeutics has a 12-month low of $0.70 and a 12-month high of $3.40. The stock has a market cap of $344.82 million, a P/E ratio of -1.85 and a beta of 1.02. The company has a 50-day moving average of $2.15 and a two-hundred day moving average of $2.30.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.10. The company had revenue of $73.83 million during the quarter, compared to analysts’ expectations of $51.90 million. As a group, analysts forecast that Esperion Therapeutics will post -0.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ESPR. Private Portfolio Partners LLC bought a new position in Esperion Therapeutics during the fourth quarter worth $30,000. BOKF NA bought a new position in shares of Esperion Therapeutics during the second quarter valued at approximately $26,000. Xponance Inc. bought a new stake in shares of Esperion Therapeutics in the 2nd quarter worth approximately $28,000. CVI Holdings LLC acquired a new position in Esperion Therapeutics during the 1st quarter valued at approximately $37,000. Finally, Simplicity Wealth LLC bought a new position in Esperion Therapeutics during the 1st quarter worth $44,000. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.